InSilico Medicine Cayman TopCo

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. InSilico Medicine Cayman TopCo has a strategic collaboration agreement with Takeda to use its proprietary Pharma.AI, to advance drug candidates. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.